OxFORD Asset Management LLP decreased its holdings in shares of Immune Design Corp. (NASDAQ:IMDZ) by 55.2% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 43,529 shares of the biotechnology company’s stock after selling 53,699 shares during the period. OxFORD Asset Management LLP owned about 0.17% of Immune Design Corp. worth $424,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the business. Renaissance Technologies LLC grew its position in shares of Immune Design Corp. by 170.0% during the first quarter. Renaissance Technologies LLC now owns 111,740 shares of the biotechnology company’s stock worth $760,000 after acquiring an additional 70,351 shares during the last quarter. Victory Capital Management Inc. grew its position in shares of Immune Design Corp. by 2.1% during the second quarter. Victory Capital Management Inc. now owns 1,977,564 shares of the biotechnology company’s stock worth $19,281,000 after acquiring an additional 40,010 shares during the last quarter. Wells Fargo & Company MN grew its position in shares of Immune Design Corp. by 46.5% during the first quarter. Wells Fargo & Company MN now owns 148,887 shares of the biotechnology company’s stock worth $1,012,000 after acquiring an additional 47,266 shares during the last quarter. Franklin Resources Inc. grew its position in shares of Immune Design Corp. by 2.7% during the second quarter. Franklin Resources Inc. now owns 760,253 shares of the biotechnology company’s stock worth $7,412,000 after acquiring an additional 20,000 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its position in shares of Immune Design Corp. by 118.7% during the second quarter. JPMorgan Chase & Co. now owns 530,702 shares of the biotechnology company’s stock worth $5,175,000 after acquiring an additional 288,009 shares during the last quarter. Hedge funds and other institutional investors own 51.46% of the company’s stock.

Several research firms have recently commented on IMDZ. ValuEngine lowered shares of Immune Design Corp. from a “sell” rating to a “strong sell” rating in a research report on Saturday. Wells Fargo & Company lowered shares of Immune Design Corp. from an “outperform” rating to a “market perform” rating and lowered their price target for the stock from $29.00 to $10.00 in a research report on Tuesday. Royal Bank Of Canada began coverage on shares of Immune Design Corp. in a research report on Thursday, September 14th. They set an “outperform” rating and a $20.00 price target for the company. BidaskClub lowered shares of Immune Design Corp. from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 5th. Finally, Zacks Investment Research upgraded shares of Immune Design Corp. from a “hold” rating to a “buy” rating and set a $11.00 price target for the company in a research report on Tuesday, July 18th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $14.75.

In related news, major shareholder Leo Guthart bought 10,000 shares of Immune Design Corp. stock in a transaction on Thursday, October 19th. The shares were purchased at an average price of $6.09 per share, for a total transaction of $60,900.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 20.70% of the stock is owned by company insiders.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/10/21/oxford-asset-management-llp-sells-53699-shares-of-immune-design-corp-imdz.html.

Immune Design Corp. (NASDAQ IMDZ) opened at 5.20 on Friday. The stock’s 50 day moving average is $9.97 and its 200 day moving average is $8.57. The company’s market cap is $133.22 million. Immune Design Corp. has a 52-week low of $4.50 and a 52-week high of $13.05.

Immune Design Corp. (NASDAQ:IMDZ) last announced its earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.54) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.65) by $0.11. Immune Design Corp. had a negative return on equity of 59.14% and a negative net margin of 324.33%. The company had revenue of $0.73 million during the quarter, compared to analyst estimates of $1.50 million. On average, analysts predict that Immune Design Corp. will post ($2.29) earnings per share for the current fiscal year.

Immune Design Corp. Profile

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.

Want to see what other hedge funds are holding IMDZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immune Design Corp. (NASDAQ:IMDZ).

Institutional Ownership by Quarter for Immune Design Corp. (NASDAQ:IMDZ)

Receive News & Stock Ratings for Immune Design Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp. and related stocks with our FREE daily email newsletter.